Pfizer reiterated at outperform by Bear Stearns

Bear Stearns analyst John Bons reiterates Pfizer Inc. at outperform with a $30 price target based on the assumption that the '995 patent will be reissued and that Lipitor will have exclusivity though 2011. Shares of the New York-based pharmaceutical company were down 10 cents, or 0.39%, at $25.51, on volume of 28,400,800 shares versus the three-month running average of 28,415,000 shares. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.